| Literature DB >> 27445535 |
Qiongya Mo1, Bingbin Wang1, Nian Dong1, Lianmin Bao1, Xiaoqiong Su1, Yuping Li1, Chengshui Chen1.
Abstract
Pulmonary alveolar proteinosis (PAP) is a rare interstitial lung disease characterized by the abnormal alveolar accumulation of surfactant components. The diagnosis of PAP can be easily missed since it is rare and lacks specific clinical symptoms. It is of great importance to have a better understanding of the crucial clue to clinically diagnose PAP and take PAP into consideration in the differential diagnosis of interstitial pulmonary diseases or other diseases with similar manifestations. Here, we analyze the clinical characteristics of 11 cases of PAP patients in local hospital and review the relevant literature in order to provide more information in diagnosis and management of PAP. In our observation, cyfra21-1 and neuron-specific enolase (NSE) known as tumor markers probably can be useful serum markers for diagnosis of PAP. As for the method of pathologic diagnosis, open-lung biopsy was the gold standard but now it is less required because findings on examination of bronchoalveolar lavage fluid (BALF) can help to make the diagnosis. We also have deep experience about when and how to carry out lung lavage.Entities:
Mesh:
Year: 2016 PMID: 27445535 PMCID: PMC4904541 DOI: 10.1155/2016/4021928
Source DB: PubMed Journal: Can Respir J ISSN: 1198-2241 Impact factor: 2.409
Clinical characteristics of PAP patients.
|
| |
|---|---|
| Age, year | 51 (30–66) |
| Gender | |
| Male | 7 (64) |
| Female | 4 (36) |
| Smoking status | |
| Never smoker | 4 (36) |
| Current or ex-smoker | 7 (64) |
| Dust exposure | 2 (18) |
| Disease duration, month | 8 (0.25–60) |
| Clinical symptoms | |
| Asymptomatic | 1 (9) |
| Symptomatic | |
| Dyspnea | 10 (91) |
| Cough | 8 (73) |
| Chest | 2 (18) |
| Fever | 4 (36) |
| Physical examination | |
| Inspiratory crackle | 6 (55) |
| Digital clubbing | 5 (45) |
| Cyanosis | 2 (18) |
| Normal | 2 (18) |
Clinical examinations of PAP patients.
| Patient number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Laboratory tests | |||||||||||
| CRP (mg/L) | 3.5 | 23.3 | 9.5 | 1.0 | 4.7 | 1.0 | 21.1 | 2.7 | 1.6 | 6.5 | 5.0 |
| ESR (mm/h) | 22 | 3 | 12 | 16 | 38 | 16 | 37 | 2.0 | 2.0 | 34.0 | 25.0 |
| PaO2 (mmHg) | 62.5 | 48.5 | 75.5 | 54.3 | 59.8 | 61.2 | 63.0 | 81 | 68.8 | 62.2 | 77.4 |
| P(A-a)O2 (mmHg) | 50.6 | 140 | 21.5 | 50.8 | 48.2 | 36.8 | 42.3 | 7.9 | 34.6 | 31.7 | 41.0 |
| LDH (U/L) | 206 | 463 | 244 | 310 | 348 | 279 | 268 | 299 | 233 | 301 | 230 |
| CEA (ng/mL) | 4.0 | 13.3 | 2.3 | 5.1 | 8.2 | 41.8 | 5.6 | 45.0 | 6.0 | 6.9 | 4.0 |
| Cyfra 21-1 (ng/mL) | 7.1 | 33.8 | 6.9 | 21.6 | 12.8 | 12.7 | 13.0 | NA | NA | NA | NA |
| NSE (ng/mL) | 17.5 | 24.4 | 17.6 | 15.0 | 19.0 | 21.5 | 24.0 | 21.0 | NA | NA | NA |
| Lung function | |||||||||||
| FEV1/FVC (%) | 94.3 | 89.9 | 94.3 | 91.1 | 74.2 | 80.9 | 88.6 | 85.7 | NA | 95.4 | 100 |
| TLC (% predicted) | 65.3 | 60.4 | 71.8 | 46.4 | 54.2 | 64.2 | 78.5 | 89.6 | NA | 60.1 | 65.1 |
| FRC (% predicted) | 62.7 | 60.0 | 92.2 | 51.7 | 42.8 | 42.8 | 74.2 | 112 | NA | 37.4 | 46.4 |
| VC (% predicted) | 68.0 | 63.2 | 73.9 | 64.8 | 58.6 | 89.1 | 74.4 | 85.9 | NA | 62.5 | 88.9 |
| DLCO (% predicted) | 44.0 | 24.2 | 40.9 | 22.4 | 28.7 | 56.1 | 46.6 | 50.4 | NA | 36.5 | 41.7 |
| mMRC score | 2 | 3 | 1 | 3 | 2 | 0 | 1 | 1 | 3 | 3 | 2 |
| Diagnosis method | |||||||||||
| Surgical biopsy | + | + | − | + | + | NA | NA | NA | NA | NA | NA |
| Transbronchial biopsy | NA | NA | NA | NA | NA | − | + | NA | − | − | NA |
| BALF | + | + | + | NA | NA | + | + | + | + | + | + |
| Clinical course | R | R | SR | R | R | SR | R | R | S | R | R |
NA: not available; R: remission; SR: spontaneous remission; S: stabilization; mMRC: modified British medical research council score for shortness of breath.
Therapeutic evaluation of WLL.
| Patient number | 1 | 2 | 4 | 5 | 7 | 8 | 10 | 11 |
|---|---|---|---|---|---|---|---|---|
| Before WLL | ||||||||
| DLCO (%) | 44.0 | 24.2 | 22.4 | 28.7 | 46.5 | 50.4 | 36.5 | 41.7 |
| PaO2 (mmHg) | 62.5 | 48.5 | 54.3 | 59.8 | 63.0 | 81 | 62.2 | 77.4 |
| mMRC score | 2 | 3 | 3 | 2 | 1 | 1 | 3 | 2 |
| WLL (left) | 9.74 L | NA | 10.9 L | — | 13 L | — | 12 L | 13 L |
| WLL (right) | 9.8 L | NA | 9 L | 1.5 L | 13 L | 6 L | 15L | 12 L |
| After WLL | ||||||||
| DLCO (%) | 45.0 | NA | 36.8 | 30.1 | 56.0 | 51.6 | 48.6 | 59.3 |
| PaO2 (mmHg) | 63.2 | NA | 61.2 | 77.4 | 95.6 | 83.5 | 78.3 | 80.3 |
| mMRC score | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
NA: not available; mMRC: modified British medical research council score for shortness of breath.